Author Topic: (Excerpt) LDN study inconclusive  (Read 48 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 8516
  • MS diagnosed 1980
  • Location: Pacific Northwest
(Excerpt) LDN study inconclusive
« on: May 18, 2017, 04:08:12 pm »
From PubMed, May 18, 2017:
The Use of Naltrexone in Low Doses Beyond the Approved Indication [Internet].

Ringerike T, Pike E, Nevjar J, Klemp M.


Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2015 Apr. Report from Norwegian Knowledge Centre for the Health Services (NOKC) No. 8-2015.
NIPH Systematic Reviews: Executive Summaries.


In Norway, naltrexone is approved as supportive treatment of alcohol dependence. The recommended dose is 50 mg, equivalent to the marketed tablet. Naltrexone in much lower doses than 50 mg has been used in Norway for the treatment of a variety of diseases, such as multiple sclerosis (MS), Crohn's disease, fibromyalgia, cancer, inflammatory bowel disease, chronic fatigue syndrome, and amyotrophic lateral sclerosis. Doses of 3 to 5 mg per day have often been termed low dose naltrexone. This use is beyond the approved indication.

The purpose of this report is to examine whether there is a documented effect of the use of naltrexone in low doses. We summarized data from a systematic review and several randomized controlled and prospective controlled studies in order to investigate the effect of using naltrexone in low doses on illness, and on functioning in daily life and to examine the risk of side effects. We identified studies for people with:Crohn's disease (one systematic review, two studies); multiple sclerosis (two studies); fibromyalgia (two studies); cancer (one study). HIV (one study); various pain conditions (three studies); opioid dependence (six studies).

All studies were either small, of short duration, or had other methodological limitations. We considered the documentation to have very low quality. That means that we cannot conclude whether the use of naltrexone in low doses is effective or safe.

MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.


Related Topics

  Subject / Started by Replies Last post
0 Replies
Last post March 28, 2016, 02:42:37 pm
by agate
0 Replies
Last post April 21, 2016, 05:17:20 pm
by agate
1 Replies
Last post June 09, 2016, 08:57:33 pm
by agate
0 Replies
Last post December 19, 2016, 08:04:13 am
by agate
0 Replies
Last post December 15, 2017, 09:27:30 am
by agate